0000000001083272

AUTHOR

Fady Farag

0000-0002-9945-1914

showing 1 related works from this author

Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

2021

Background: Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. Objective: We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. Methods: We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan–Meier curves. Cox proportional models were used for univariate and multivariate analyses. Results: We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from …

MaleOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisCabozantinibPyridineschemistry.chemical_compoundRenal cell carcinomaInternal medicinemedicineHumansAnilidesPharmacology (medical)Carcinoma Renal CellSarcomatoid DifferentiationRetrospective Studiesbusiness.industryHazard ratioCell Differentiationmedicine.diseaseKidney NeoplasmsConfidence intervalOncologychemistryMale patientFemalebusinessKidney cancerTargeted Oncology
researchProduct